ArticleClinical and experimental nephrology2026
Renin-related changes after sequential switching from aliskiren to valsartan and sacubitril/valsartan in patients with a high-renin phenotype: a prospective pilot study.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA high-renin phenotype suggests renin-dependent activation of the renin-angiotensin-aldosterone system (RAAS), for which direct renin inhibition may be a mechanistically relevant approach. After discontinuation of aliskiren in Japan, aliskiren-treated patients required transition to alternative RAAS inhibitors. We evaluated renin-related changes during sequential switching from aliskiren to valsartan and sacubitril/valsartan.
methodsThis single-center, prospective, open-label pilot study included aliskiren-treated patients with a high-renin phenotype. Patients were switched to valsartan for 8 weeks and then to sacubitril/valsartan for 16 weeks. Plasma renin activity (PRA), active renin concentration (ARC), and plasma aldosterone concentration (PAC) were assessed with blood pressure, estimated glomerular filtration rate (eGFR), and echocardiographic parameters. Hormonal variables are shown as medians [25th-75th percentiles].
trial registrationUMIN000057149.
resultsEight patients (median age, 47.5 years; 50% male) were analyzed. After switching to valsartan, PRA increased from 0.6 [0.1-2.5] to 5.5 [3.2-15.8] ng/mL/h, and ARC increased from 2.5 [0.8-7.7] to 20.2 [16.9-45.6] pg/mL, whereas no further marked increase was observed during sacubitril/valsartan treatment. PAC did not change significantly. Systolic blood pressure increased during the valsartan phase and decreased after sacubitril/valsartan initiation. eGFR showed no progressive deterioration. Left atrial volume index increased at 24 weeks, whereas other filling pressure indices did not change.
conclusionIn this small prospective pilot study, sequential transition from aliskiren to valsartan and sacubitril/valsartan was associated with renin-related changes without progressive renal deterioration. These preliminary findings may help characterize RAAS-related responses during treatment transition in selected patients with a high-renin phenotype.
Indexed as
Identifiers
42611097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.